Cover Image

A comparative Study on Phenotypic detection of Amp-C Beta Lactamases and Extended Spectrum Beta Lactamases in Gram Negative Bacterial urine isolates in a tertiary care hospital



Abstract : The prevalence of multi drug resistant Gram  Negative bacteria has increased in the past few years and the bacterial strains producing Amp-C Beta Lactamase and     Extended Spectrum Beta Lactamase are of particular concern(1). With the increase in occurrence and different types of these multiple -lactamase enzymes, early detection is crucial. The benefits of which include implementation of proper antibiotic therapy and to frame infection control policy. Amp C Beta  lactamase confer resistance to aminopencillins, cephalosporin, oxyimino-cephalosporins (cefoxitin cefotetan) and monobactams and are not affected by clavulanic acid like Extended Spectrum Beta Lactamase producers The objective of the present study is to screen and phenotypically detect Amp-C Beta Lactamase and Extended Spectrum Beta Lactamase in Gram Negative Bacterial urine isolates. Out of the 100 cefoxitin and ceftazidime resistant strains taken for study 71 were found to produce Amp-C Beta lactamase 81 strains were found to produce ESBL. 17 strains were resistant to both cefoxitin­cloxacillin combination disc and ceftazidime-clavulanic acid disc. They are subjected to  meropenem sensitivity and the results were analysed

Keyword :Key words ESBL, Amp C Beta lactamase,  combination disc.


Full Text:




Phenotypic detection of extended-spectrum and AmpC-lactamases by a new spot-inoculation method and modified three-dimensional extract test: comparison with the conventional three-dimensional extract test M. Shahid*, Abida Malik, Mithlesh Agrawal and Sanjay Singhal

AmpC Disk Test for Detection of Plasmid-Mediated AmpC -Lactamases in Enterobacteriaceae Lacking Chromosomal AmpC -Lactamases Jennifer A. Black, Ellen Smith Moland and Kenneth S. Thomson*

Hugbo PG, Olurinola PF (1992). Resistance of Pseudomonas aeruginosa to Antimicrobial agents: Implications in Medicine and Pharmacy. Nig. J. Pharm. Sci. 4: 1-10.

Chastre J trouillet,Problem pathogens(Pseudomonas aeruginosa and Acinetobacter)Semin Respiratory infection2000; 15,289-97.

Detection of AmpC Beta-Lactamase in Escherichia coli: Comparison of Three Phenotypic Confirmation Assays and Genetic Analysis. S. Peter-Getzlaff, S. Polsfuss, M. Poledica,‡ M. Hombach, J. Giger, E. C. Böttger, R. Zbinden, and G. V. Bloemberg* J. Clin. Microbiol. 2011, 49(8):2924. DOI: 10.1128/JCM.00091-11. Published on 8 June 2011

Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmwere? Clin Infect Dis 2002;34: 634–40.

Weldhagen GF, Poirel L, Nordmann P. Ambler class A extended-spectrum b-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact. Antimicrob Agents Chemother 2003;47: 2385–92.

AmpC b-Lactamases Clin. Microbiol. Rev. 2009, 22(1):161. DOI: George A. Jacoby 10.1128/CMR.00036-08.

Washington Winn Jr, Stephen Allen, William Janda, Elmer Koneman ,Gary Procop, Paul Schreckenberger, Gail Woods; Koneman’s Colour Atlas and Textbook Of Diagnostic Microbiology, 6th Edition; Chapter 7,pg 303-391.

Bauer .A.W, Kirby WMM, Sherris JC and Turck.M,1966;Antibiotic Susceptibility By Standardized Single Disc Diffusion Method.Am J Clinical pathology,45;493-96.

Pitout JD, Gregson DB, Poirel L,Mc Clure JA, Le P, Church DL; Detection of Pseudomonas aeruginosa producing Metallo-Beta Lactamases in a large centralized laboratory.;J of Clinical microbiology,2005:43;3129-35. .

Monica Cheesbrough District Laboratory Practice in Tropical Countries Part-2 District Laboratory Practice in Tropical Countries Part 2 Second Edition Cambridge University Press

Jamshaid ali khan, Zafar iqbal, Saeed ur rahman, Kalsoom farzana and Abbas khan Prevalence And Resistance Pattern Of Pseudomonas aeruginosa Against Various Antibiotics ;Pak. J. Pharm. Sci., Vol.21, No.3, July 2008, pp.311-315.

Bonfiglio, G. & Marchetti, F. (2000). In vitro activity of Ceftazidime, Cefepime and Imipenem on Pseudomonas aeruginosa Clinical isolates either susceptible or resistant to Betalactams. Chemotherapy 46, 229–34.

John Smith MB, John Payne E, Thomas Berne V (2000).The surgeons Guide to antimicrobial Chemotherapy, pp.38-74.

Viren A Javiya,Somsuvra B.Gatak,Kamlesh R .Patel,Jagruthi R Patel, Antibiotic Susceptibility Pattern Of Pseudomonas aeruginosa In A Tertiary Cwere Hospital In Gujarat, India.Indian J of Pharmacology, October 2009,vol 40,issue 5,230-34.

Bailey and Scott’s Diagnostic Microbiology;Twelfth edition,Chapter 57,Urinary Tract Infection;842-855.

National Nosocomial Infections Surveillance (NNIS) System Report, Data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32:470–85.

Supriya Upadhyay, Malay Ranjan Sen, Amitabha Bhattacharjee: Presence of different beta­lactamase classes among Clinical isolates of Pseudomonas aeruginosa expressing AmpC beta­lactamase enzyme J Infect Dev Ctries 2010; 4(4):239-242.

Ritu Aggarwal, Uma Chaudary,Kiran Bala; Detection of Extended Spectrum Lactamase in Pseudomonas aeruginosa; IJPM.51(2),April-June 2008,222-24.

National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from . From October 1986 to December 1990,Am J Infect Control.

Clinical and Laboratory Standards Institute, Performance Standards for Antimicrobial Susceptibility Testing: seventeenth Informational Supplement ;M100-S17.

Washington Winn Jr, Stephen Allen, William Janda, Elmer Koneman ,Gary Procop, Paul Schreckenberger, Gail Woods ;Koneman’s Colour Atlas and Textbook Of Diagnostic Microbiology, 6th Edition; Chapter 17,pg 945-1021.


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

An Initiative of The Tamil Nadu Dr M.G.R. Medical University